Despite the increase in effectiveness of systemic therapy, cure for colorectal cancer with liver metastases (CRLM) is rarely achieved without surgical resection, with less than 20% of patients initially suitable for surgery. Liver-directed therapies are continually being investigated in the hope of improving cure rates in patients with unresectable liver metastases. These modalities include selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and hepatic artery infusion (HAI) chemotherapy. While there is evidence of activity for all these treatments, they are somewhat lacking in high level randomized, controlled trial evidence (RCT) with appropriate control arms relevant to curre...
Liver is the main target for colorectal cancer (CRC) metastases. About 50% of all patients affected ...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...
AbstractSystemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant dev...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
Ideally, tumors that might cause morbidity and mortality should be treated, preferably early, with p...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract In pat...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy ...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
Systemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant development...
Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the ...
Item does not contain fulltextOBJECTIVE: To evaluate and compare the overall survival (OS) in case-m...
AbstractSystemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant dev...
Liver is the main target for colorectal cancer (CRC) metastases. About 50% of all patients affected ...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...
AbstractSystemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant dev...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
(1) Background: colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide....
Ideally, tumors that might cause morbidity and mortality should be treated, preferably early, with p...
# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract In pat...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy ...
Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop liver meta...
Systemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant development...
Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the ...
Item does not contain fulltextOBJECTIVE: To evaluate and compare the overall survival (OS) in case-m...
AbstractSystemic therapy for colorectal cancer liver metastases (CRLM) has undergone significant dev...
Liver is the main target for colorectal cancer (CRC) metastases. About 50% of all patients affected ...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...
Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The...